140 related articles for article (PubMed ID: 37093412)
21. Effects of preoperative albumin-to-globulin ratio on overall survival and quality of life in esophageal cell squamous carcinoma patients: a prospective cohort study.
Zhang J; Lin Z; Zhou J; Huang Y; Chen S; Deng Y; Qiu M; Chen Y; Hu Z
BMC Cancer; 2023 Apr; 23(1):342. PubMed ID: 37055773
[TBL] [Abstract][Full Text] [Related]
22. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
Hong ZN; Huang Z; Weng K; Lin J; Kang M
Front Immunol; 2022; 13():1036396. PubMed ID: 36311738
[TBL] [Abstract][Full Text] [Related]
23. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS
Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254
[TBL] [Abstract][Full Text] [Related]
24. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
[TBL] [Abstract][Full Text] [Related]
25. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial.
Javed A; Pal S; Dash NR; Ahuja V; Mohanti BK; Vishnubhatla S; Sahni P; Chattopadhyay TK
J Gastrointest Cancer; 2012 Mar; 43(1):63-9. PubMed ID: 20835926
[TBL] [Abstract][Full Text] [Related]
26. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
[TBL] [Abstract][Full Text] [Related]
27. Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.
Sun T; Huang S; Jiang Y; Yuan H; Wu J; Liu C; Zhang X; Tang Y; Ben X; Tang J; Zhou H; Zhang D; Xie L; Chen G; Zhao Y; Wang S; Xu H; Qiao G
Front Bioeng Biotechnol; 2022; 10():1010672. PubMed ID: 36277407
[No Abstract] [Full Text] [Related]
28. Self-expanding plastic stent removed after radiochemotherapy for advanced esophageal cancer.
Laquière A; Grandval P; Heresbach D; Prat F; Arpurt JP; Bichard P; D'Halluin PN; Berthillier J; Boustière C; Laugier R
Dis Esophagus; 2014; 27(2):176-81. PubMed ID: 23651038
[TBL] [Abstract][Full Text] [Related]
29. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
30. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.
Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M
Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767
[TBL] [Abstract][Full Text] [Related]
31. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
[TBL] [Abstract][Full Text] [Related]
32. Pathological Responses of the Primary Tumor and Locoregional Lymph Nodes After Neoadjuvant Immunochemotherapy in Esophageal Squamous Cell Cancer.
Huang SJ; Tian D; Wang SC; Zeng RJ; Dong YJ; Hong LL; Wu HS; Xu FP; Zhang DK; Xie L; Zhou HY; Tang JM; Ben XS; Chen G; Chen RX; Tang Y; Qiao GB
World J Oncol; 2022 Aug; 13(4):195-204. PubMed ID: 36128590
[TBL] [Abstract][Full Text] [Related]
33. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
34. Preliminary Results of Temporary Placement of Retrievable Expandable Metallic Stents during Preoperative Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer.
Park JH; Song HY; Shin JH; Kim JH; Kim YH; Kim SB; Kim JH
J Vasc Interv Radiol; 2015 Jun; 26(6):883-8. PubMed ID: 25724088
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
36. Elevated Preoperative NMPR Predicts an Unfavorable Chance of Survival in Resectable Esophageal Squamous Cell Carcinoma.
Peng MY; Zuo ZG; Cao FJ; Yu YD; Cai XJ; Wan GX
Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557010
[TBL] [Abstract][Full Text] [Related]
37. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
38. The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.
Ning ZH; Zhao W; Li XD; Chen LJ; Xu B; Gu WD; Shao YJ; Xu Y; Huang J; Pei HL; Jiang JT
Int J Clin Exp Pathol; 2015; 8(6):6881-90. PubMed ID: 26261575
[TBL] [Abstract][Full Text] [Related]
39. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
